Oncimmune Holdings Valuation

Is ONC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ONC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ONC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ONC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ONC?

Key metric: As ONC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ONC. This is calculated by dividing ONC's market cap by their current revenue.
What is ONC's PS Ratio?
PS Ratio	13.7x
Sales	UK£1.21m
Market Cap	UK£16.60m

ONC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	17.3x
Enterprise Value/EBITDA	-18.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ONC's PS Ratio compare to its peers?

The above table shows the PS ratio for ONC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	9.2x
OPTI OptiBiotix Health	22.8x	n/a	UK£13.0m
PBX ProBiotix Health	5x	n/a	UK£10.7m
APTA Aptamer Group	6.6x	n/a	UK£5.7m
VRCI Verici Dx	2.4x	78.8%	UK£8.2m
ONC Oncimmune Holdings	13.7x	105.1%	UK£16.6m

Price-To-Sales vs Peers: ONC is expensive based on its Price-To-Sales Ratio (13.7x) compared to the peer average (9.2x).

Price to Sales Ratio vs Industry

How does ONC's PS Ratio compare vs other companies in the GB Biotechs Industry?

5 Companies	Price / Sales	Estimated Growth	Market Cap
GNS Genus	1.7x	3.5%	US$1.40b
OXB Oxford Biomedica	4.4x	21.0%	US$544.58m
TRX Tissue Regenix Group	1.7x	15.1%	US$54.78m
VRCI Verici Dx	2.4x	78.8%	US$10.32m

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: ONC is expensive based on its Price-To-Sales Ratio (13.7x) compared to the European Biotechs industry average (7.8x).

Price to Sales Ratio vs Fair Ratio

What is ONC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ONC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	13.7x
Fair PS Ratio	49.4x

Price-To-Sales vs Fair Ratio: ONC is good value based on its Price-To-Sales Ratio (13.7x) compared to the estimated Fair Price-To-Sales Ratio (49.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Regeneron Pharmaceuticals

US$81.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$754.00

-8.8%

-6.0%

hVIVO

UK£178.6m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.25

-10.9%

39.6%

Dermapharm Holding

€1.9b

Manufactures and sells off-patent branded pharmaceutical products in Germany.

0A5J

€34.28

7.4%

-14.7%